Meeting Report

Report on the Korean Association of Immunologists (KAI) International Meeting 2021 Hybrid, June 2-4

The Annual International Meeting of Korean Association of Immunologists (KAI 2021) was held on June 2 – 4, 2021 at the Swiss Grand Hotel in Seoul, Korea. Despite the continuing global COVID-19 pandemic and a strict social distancing policy in Korea, the on/offline hybrid meeting was highly successful with about 900 participants (181 abstracts) from 21 countries. The scientific program included 4 plenary lectures, 14 Major Symposia, 3 Satellite Symposia, 6 Workshops, 2 Education Sessions, and many Industry Symposia. The plenary lectures were given by Mi-Na Kwon (Korea), Laurence Zitvogel (France), Mark Davis (USA), and Ruslan Medzhitov (USA). More information on KAI 2021 can be found at https://kai2021.org/register/KAI2021/main.html. KAI 2022 is planned to be held on Nov. 3 – 5, 2022 at the Dragon City Hotel in Seoul, Korea.

The Korean Association of Immunologists (KAI) is the national society of immunology researchers that includes basic immunologists and clinicians. KAI started in1974 with 48 inaugural members and has grown to have more than 3,000 current members. This year KAI is sponsoring one scientific session at Cytokines 2021 on Cytokines and Bystander T Cell Activation.

[READ MORE]

Members in the News
Members in the News

Three ICIS Members elected to the National Academy of Sciences for their contributions to epidemiology, innate immunity and immunology – Congratulations!

Three ICIS Members elected to the National Academy of Sciences for their contributions to epidemiology, innate immunity and immunology – Congratulations to Ralph S. Baric, William R. Kenan Jr. , Katherine A. Fitzgerald, and Ellen V. Rothenberg http://www.nasonline.org/ Twitter: @theNASciences [READ MORE]

Young Investigators to Watch...2022 Winners
Special Article of Interest

The Delta Trick of COVID-19

Since the first report of SARS-CoV-2 from Wuhan, back in December 2019, the pandemic has ravaged the world with ever-evolving different variants-with changing dominance patterns. Different variant of concerns (alpha, beta, gamma, delta and kappa) with corresponding spike mutations, rendering evasion of the immune system and making them varyingly resistant to different vaccines (1). Presently, the delta variant (B.1.617.2) has outcompeted the other variants of concern and is globally the most intimidatingly dominant one. [READ MORE]

Young Investigators to Watch...2022 Winners

Cytokines 2021 Virtual Meeting Abstract Award Winners

Announcing the Cytokines 2021 Virtual Meeting Milstein Abstract Award Winners Powered By EmbedPress Announcing the Cytokines 2021 Virtual Meeting EFIS Trainee Abstract Awards European Federation of Immunological Societies and the European Journal of Immunology Travel/Abstract Awards Available for trainees and postdoc presenters who are currently working in Europe or the UK. [READ MORE]

Members in the News
Welcome New Members

Welcome New Members

We welcome these new members to the ICIS and we look forward to their attendance at the annual meeting and involvement in the society. The ICIS Membership Committee and Council especially thanks the Sponsoring Members and Research Advisors noted below. As of October 1, 2022, there are 970 ICIS Members in [READ MORE]

Industry News

By Supreet Agarwal Cytokines represent the major class of all the soluble ligands targeted by FDA-approved drugs  Major cytokines’ (interferons, interleukins and chemokines) targeted therapies Figures adapted from: Attwood, M.M., Jonsson, J., Rask-Andersen, M. et al. Soluble ligands as drug targets.  Nat Rev Drug Discov 19, 695–710 (2020). https://doi.org/10.1038/s41573-020-0078-4 Cytokines based therapies approved in [READ MORE]